ライフサイエンスコーパス: skin rash

1 discontinued treatment because of toxicity (skin rash).

2 in 5/6 pigs including diarrhoea, emesis, and skin rash.

3 eactive T-cell clones in skin at the time of skin rash.

4 luding fever, night sweats, weight loss, and skin rash.

5 l recognition in patients presenting without skin rash.

6 prophylactic treatment of erlotinib-induced skin rash.

7 l fibroelastosis, 1 degrees CHB at birth and skin rash.

8 AL-PEG (0.100 mg/kg) developed a generalised skin rash.

9 bexarotene-induced hypertriglyceremia and/or skin rash.

10 xarotene-induced hypertriglyceridemia and/or skin rash.

11 ose reductions of erlotinib due to grade 2/3 skin rash.

12 oxicities were mild hypertriglyceridemia and skin rash.

13 is a commonly occurring, intensely pruritic skin rash.

14 tion of viremia and developed a desquamating skin rash.

15 syndrome, and two patients (5%) had grade 3 skin rash.

16 atient experienced a reactivation-associated skin rash.

17 XCR3+ T cells to skin, were overexpressed in skin rashes.

18 ents were lymphocytopenia (19 [14%] of 131), skin rash (16 [12%]), thrombocytopenia (12 [9%]), infect

19 adverse events in the trametinib group were skin rash (17 [13%] of 128), anaemia (16 [13%]), hyperte

20 The most commonly reported symptoms were skin rash (18 [86%] of 21) and fever (12 [57%]).

21 w transplant (seroconversion, HHV-6 viremia, skin rash); 18 of 20 had increased peripheral blood mono

22 .98), acute renal failure (2.56; 1.55-4.25), skin rash (2.42; 2.13-2.75), urticaria (1.37; 1.19-1.57)

23 he most common grade 3-4 adverse events were skin rash (21 [27%] of 77 patients vs 20 [22%] of 92 pat

24 fever (43%), anorexia (33%), fatigue (33%), skin rash (21%), stomatitis (14%), and allergic reaction

25 hesia syndrome (38.1%), alopecia (26.2%) and skin rash (23.8%).

26 pulmonary toxicity were common, and included skin rash (38%), peripheral eosinophilia (38%), liver dy

27 Other grade 3 or 4 toxicities included skin rash (4 patients, 10%), peripheral neuropathy (2 pa

28 The most common grade 3 or 4 toxicity was skin rash (45%), followed by neutropenia (21%) without f

29 rade 3 treatment-related adverse events were skin rash (47%) and diarrhea (20%).

30 ted symptoms were fever (49 [80%] of 61) and skin rash (48 [79%]).

31 Grade 3-4 immune-related adverse events were skin rash (6%), colitis (3%), and hypophysitis (3%).

32 itis/stomatitis (6%), constipation (6%), and skin rash (6%).

33 grade 3 event during maintenance therapy was skin rash (7.2%).

34 de >= 3 event during maintenance therapy was skin rash (7.2%).

35 vae (100%), fever (100%), fatigue (87%), and skin rash (75%).

36 Percentage of common toxicities were skin rash, 86% and 72%; fatigue, 51% and 44%; and AST/AL

37 The most common adverse effects were skin rash (9.1%) and fatigue (8%).

38 Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%).

39 on 2 girls with periodic episodes of fever, skin rash, abdominal pain, and arthralgia, of whom 1 had

40 Patient 2, a female in her 60s, developed a skin rash about 2.5 h after ingesting wild boar meat.

41 de female predominance, presence of fever or skin rash, absence of subcutaneous nodules or finger clu

42 Skin rash also correlated with drug levels and tended to

43 ghlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir

44 nflammatory syndrome characterized by fever, skin rash and arthritis affecting children and adults.

45 Grade 1/2 skin rash and diarrhea were the most frequent treatment-

46 ght (53%) experienced grade 1 to 2 acne-like skin rash and diarrhea, but no grade 3 or 4 toxicity occ

47 ne protected 80% of the infant macaques from skin rash and MV-induced immunosuppression.

48 1-blind MV, viremia was short-lived, and the skin rash and other clinical signs observed with wild-ty

49 dverse events were <10%, consisting of minor skin rash and pruritus associated with the patch.

50 All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGF

51 One woman in the placebo group reported a skin rash and two women in the amoxicillin and clavulani

52 rile neutropenia, hypotension, myalgias, and skin rash and were removed from treatment more often as

53 ogical, and biological homeostasis and cause skin rashes and irritation, yet the molecular basis rema

54 itis, sensorineural hearing loss, urticarial skin rash, and a characteristic deforming arthropathy.

55 f emergency department visits for asthma and skin rash, and Culex quinquefasciatus species-specific v

56 en patients had normal liver function tests, skin rash, and diagnosis of GvHD histologically confirme

57 vere infantile-onset IBD, failure to thrive, skin rash, and perirectal abscesses refractory to medica

58 Sex, histology, skin rash, and smoking history predicted outcome with er

59 phenotype includes granulomatous arthritis, skin rash, and uveitis and probably represents a subtype

60 r, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; some patients also dev

61 ase was characterized chiefly by arthralgia, skin rashes, and AA amyloidosis.

62 , to mild infection, characterized by fever, skin rashes, and arthritis.

63 onths, including symptoms of fatigue, fever, skin rashes, and ulcers, was measured using the Systemic

64 ned with the terms "psoriasis," "pustular," "skin," "rash," and "palmoplantar." All relevant articles

65 Patients experienced fever, skin rash, arthralgia and conjunctivitis.

66 erized by high spiking fevers, leukocytosis, skin rash, arthralgia and myalgia.

67 oderate and severe allergic symptoms such as skin rashes, asthma, and even anaphylactic shock.Researc

68 The DLT was reversible hepatotoxicity and skin rash at 70 mg/m(2) per day for 5 days.

69 -4.03 [95% CI, -13.76 to 5.70]; P = .42) or skin rash (beta = -1.00 [95% CI, -6.92 to 4.92]; P = .74

70 netic disorder characterized by a congenital skin rash, birth defects of the skeleton, genomic instab

71 and hypersensitivity, diarrhea and vomiting, skin rash, clinical deterioration, and patient's wishes

72 include GI (diarrhea, anorexia, and nausea), skin rash, cytopenias, pleural effusions, and fatigue.

73 re to industrial phenolics is known to cause skin rash, dermal inflammation, contact dermatitis, leuc

74 Common adverse events were skin rash/desquamation, hand-foot skin reaction, and fat

75 The most common adverse events were skin rash, diarrhea, and fatigue.

76 Patients typically developed fever, skin rash, diarrhea, or pancytopenia within 2 to 6 weeks

77 ecipients with a clinical suspicion of GvHD (skin rash, diarrhea, pyrexia, pancytopenia, or anemia, w

78 In the rituximab group, nausea and skin rash during infusion were common; transient acute a

79 tion (three [8%]), hypertension (six [16%]), skin rash (eight [22%]), and pancreatitis (six [16%] pat

80 mptoms; however, all 3 children did manifest skin rash, fatigue, and biopsy-proven glomerulonephritis

81 Common toxicities included diarrhea, skin rash, fatigue, and hand-foot syndrome.

82 mutation (p.T132A) presented with persistent skin rash featuring hyperkeratosis, parakeratosis and ac

83 The most common adverse events were skin rash (five patients) and oedema with weight gain (s

84 n drug-related adverse events were diarrhea, skin rash, hyperglycemia, and night blindness.

85 at might contribute to the high frequency of skin rashes/hypersensitivity episodes experienced by ast

86 ss, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia.

87 ing, and diarrhea in 2 patients, and grade 3 skin rash in 1 patient.

88 e cisplatin toxicity but was associated with skin rash in a majority of patients and occasional serio

89 treatment was interrupted because of grade 3 skin rash in four patients in the placebo arm, and none

90 atively localized erythematous maculopapular skin rash in most dengue-naive vaccinees.

91 dence-based trials for EGFR antibody-induced skin rash in patients with cancer.

92 Here, we reported skin rashes in 32% of 44 patients with CTCL treated with

93 In summary, skin rash is an off-tumor, on-target effect of tebentafu

94 but mostly mild; 1 treatment-related grade 3 skin rash led to discontinuation.

95 ost common toxicities were anemia, acne-like skin rash, leukopenia, fatigue and malaise, and nausea a

96 Immunofluorescence analysis of skin rash, lungs, lymph nodes, and ganglia revealed SVV

97 Although skin rash may be a pharmacodynamic marker of drug action

98 hematologic toxicities of docetaxel included skin rashes, mucositis, and mild elevations of serum tra

99 st abnormalities, nausea/vomiting, diarrhea, skin rashes, mucositis, and palmoplantar erythrodysesthe

100 foot syndrome, diarrhea, hyperbilirubinemia, skin rash, myalgia, and arthralgia.

101 linical symptoms, including fever, headache, skin rash, myalgia, arthralgia, depression, and coma.

102 e a day (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]).

103 in no major toxicities, including absence of skin rash observed with other EGFR-directed agents.

104 Anemia, gastrointestinal side effects, and skin rashes occurred at a higher incidence among patient

105 re supported by histologic findings from the skin rash of a human subject who received an attenuated

106 gs of inflammatory myopathy, and the typical skin rash of dermatomyositis.

107 + T cells are detectable in blood and in the skin rash of secondary syphilis and persist in both comp

108 is.A 64-year-old Japanese female developed a skin rash on the hairlines of her forehead and nuchal re

109 ab group), diarrhoea (13 [10%] vs 14 [10%]), skin rash (one [1%] vs 22 [16%]), thromboembolic events

110 for neutrophil transudation during colitis, skin rash or peritonitis.

111 elta30 and DENV3Delta30, trigger a confluent skin rash over most of the body in most unvaccinated par

112 y more frequent at contrast-enhanced CT were skin rash (P = .0311), skin redness (P = .0055), skin sw

113 Skin rash, palmar-plantar erythrodysesthesia, and thromb

114 elationship to study drug, were an acne-like skin rash, predominantly on the face and upper torso (86

115 so 2 apparent treatment failures in cases of skin rash, raising questions about the efficacy or suita

116 associated vasculitis manifested by purpuric skin rashes, renal abnormalities, and elevated cryoglobu

117 Skin rash, the most frequent adverse event, affected 74%

118 ade 3 adverse event in the AZD8931 group was skin rash (three [20%] of 15 patients with available dat

119 ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease.

120 nown for their multiple health effects, from skin rashes to liver dysfunction, reproductive toxicity

121 four [4%] vs two [2%] postoperatively), and skin rash (two [1%] vs 21 [15%] preoperatively; 0 vs eig

122 Free-text answers revealed themes of "Skin Rashes", "User-satisfaction" and "Empowerment".

123 Skin rash, viremia, and the strength of the innate and a

124 Erlotinib-induced skin rash was associated with improved CFS (P = .01).

125 Variability in skin rash was best explained by a multivariate logistic

126 Skin rash was observed in 21% of patients.

127 Skin rash was the most common toxicity (grade 3, 15%).

128 (> 5 days) and/or associated with fever, and skin rashes were consistently experienced by heavily (HP

129 Skin rashes were noted in four patients treated at 20 an

130 toimmune events with the early appearance of skin rashes were observed in patients with stable diseas